Impact Factor 5.122 | CiteScore 4.04
More on impact ›
The growing understanding of the molecular mechanisms of both genetic and acquired diseases offers specific molecular targets for therapeutic intervention. The transfer of genetic material to the tissue-resident cells (gene therapy) or of healthy cells to the diseased tissue (cell therapy), as well as their combination by genetically engineered progenitors, are complementary approaches to correct the specific molecular cause of disease and restore lost function.
The "Preclinical Cell and Gene Therapy" section of Frontiers in Bioengineering and Biotechnology welcomes submissions on both basic and translational aspects of the development of innovative genetic and cellular therapies.
Areas of interest include, but are not limited to:
Indexed in: PubMed, PubMed Central, Scopus, Web of Science, Google Scholar, DOAJ, CrossRef, Chemical Abstracts Service (CAS), Semantic Scholar, Ulrich's Periodicals Directory, Science Citation Index Expanded, CLOCKSS, EI Compendex, OpenAIRE, Zetoc
Preclinical Cell and Gene Therapy welcomes submissions of the following article types: Brief Research Report, Case Report, Correction, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Review, Specialty Grand Challenge, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Preclinical Cell and Gene Therapy, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Preclinical Cell and Gene Therapy will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Bioengineering and Biotechnology.
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact firstname.lastname@example.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact email@example.com